

CONFERENCE SCHEDULE

Wednesday, September 25, 2019

Time	Session	Speakers
01:00 p.m. 01:10 p.m.	Grand Opening	Guido Kroemer
01:10 p.m. 02:00 p.m.	Keynote Lecture Immunological response of human cancers to PD-1 blockade	Ton Schumacher
Session 1: Cancer prevention and lifestyle factors in oncoimmunology Session Chairperson: Olivera J. Finn		
02:00 p.m. 04:00 p.m.	02:00 p.m. Targets of spontaneous immunosurveillance as vaccine antigens for cancer prevention	Olivera J. Finn University of Pittsburgh Cancer Institute
	02:35 p.m. Caloric restriction mimetics that support anticancer immunosurveillance	Guido Kroemer Centre de Recherche des Cordeliers
	03:05 p.m. Nociceptors control functions of dendritic cells	Pavel Hanc* Harvard Medical School
	03:30 p.m. Stress compromises therapy-induced anti-tumor immunity	Yuting Ma Suzhou Institute of Systems Medicine
04:00 p.m. 04:30 p.m.	Coffee Break	

*proffered abstract

Wednesday, September 25, 2019

Time	Session	Speakers
Session 2: Combination therapies with immune checkpoint blockers Session Chairperson: Alexander Eggermont		
04:30 p.m. 06:30 p.m.	04:30 p.m. "Lessons from the IO-Melanoma-Revolution and it's roll out across multiple tumor types"	Alexander Eggermont Gustave Roussy Cancer Center
	05:05 p.m. Reprogramming the tumor microenvironment by activation of p53 enhances anti-tumor effects of immune checkpoint blockade in preclinical models.	Arnab Ghosh* Memorial Sloan Kettering Cancer Center
	05:25 p.m. Combination immunotherapy of cancer involving therapeutic vaccination	Cornelis J.M. Melief Leiden University Medical Center and ISA Pharmaceuticals BV
	06:00 p.m. Harnessing innate immunity in cancer therapy	Eric Vivier Centre d'immunologie de Marseille-Luminy
06:30 p.m. 08:00 p.m.	Cocktail Reception	

*proffered abstract

Time	Session	Speakers
08:00 a.m. 09:00 a.m.	Coley Award Lecture	Elizabeth Jaffee
Session 3: T cell exhaustion – mechanisms: RESISTANCE MECHANISMS Session Chairperson: W. Nicholas Haining		
09:00 a.m. 11:00 a.m.	09:00 a.m. Functional genomic approaches for understanding the immune response to cancer	W. Nicholas Haining Merck Research Laboratories
	09:25 a.m. Intoxication causes T-cell exhaustion in chronic infection	Dietmar Zehn Technical University of Munich
	09:50 a.m. CD226 absence affects TCR responsiveness and restrains tumor infiltrating T lymphocyte functions.	Ludovic Martinet* Centre de recherche en Cancérologie de Toulouse
	10:10 a.m. Acquired T cell function and dysfunction in response to immunotherapy	David Brooks Princess Margaret Cancer Centre
	10:35 a.m. A Novel Class of Fully Human Bispecific Antibodies for Cancer Immunotherapy	Dimitris Skokos Regeneron Pharmaceuticals
Session 4: Immunotherapies, non-cell-based - Session Chairperson: Ira Mellman		
11:00 a.m. 01:00 p.m.	11:00 a.m. Mechanistic basis of cancer immunotherapy: checkpoints at 10	Ira Mellman Genentech
	11:25 a.m. <i>Not available at the moment of printing</i>	Ugur Sahin BioNTech
	11:50 a.m. Systems Immunology in IO: A view from the Parker Institute	Nikesh Kotecha Parker Institute for Cancer Immunotherapy
	12:15 p.m. Overcoming the Immunosuppressive Prostate Tumor Microenvironment	Sumit Subudhi The University of Texas MD Anderson Cancer Center
	12:40 p.m. Vaccination against a neoepitope whose expression is driven by acquired resistance to oncolytic virotherapy prevents VSV-resistant tumour recurrence	Richard Vile* Mayo Clinic

Time	Session	Speakers
01:00 p.m. 03:00 p.m.	Lunch 01:15 p.m. - 02:45 p.m. - Industry "Plenary Lunch Meeting 1" MILTENYI Concomitantly Poster Session A	
Session 5: Immunotherapies, cell based - Session Chairperson: Helen E. Heslop		
03:00 p.m. 04:30 p.m.	03:00 p.m. Towards the next generation of cancer vaccines	Carl G. Figdor Radboud University Nijmegen
	03:25 p.m. Genome-Wide CRISPR screens reveal SOCS-1 as a dominant intrinsic checkpoint of CD4 T cells quorum sensing	Laurie Menger* Curie Institute
	03:40 p.m. Targeting Tumors with Native and Chimeric Receptors	Helen E. Heslop Baylor College of Medicine
	04:05 p.m. Engineering Next-generation T cell Therapies for Solid Tumors	Kole Roybal University of California San Francisco
04:30 p.m. 05:00 p.m.	Coffee Break	
Session 6: New targets and concepts - Session Chairperson: Ellen Puré		
05:00 p.m. 06:30 p.m.	05:00 p.m. Targeting stroma to treat cancer and fibrosis	Ellen Puré University of Pennsylvania
	05:25 p.m. Cellular Conversations that Control Cancer	Thea D. Tlsty University of California San Francisco
	05:50 p.m. CD24 signaling through macrophage Siglec-10 is a new target for cancer immunotherapy	Amira Barkal* Stanford University
	06:05 p.m. Anti-tumor T cells, you are what you eat	Susan Kaech Salk Institute for Biological Studies
06:30 p.m. 08:00 p.m.	Poster Session A continued	

*proffered abstract

*proffered abstract

Time	Session	Speakers
Session 7: Tumor antigens - Session Chairperson: Robert D. Schreiber		
09:00 a.m. 11:00 a.m.	09:00 a.m. UVB-induced tumor heterogeneity diminishes immune response in melanoma	Yardena Samuels Weizmann Institute of Science
	09:25 a.m. The molecular cell biology of immune control and escape of tumors	Robert D. Schreiber Washington University School of Medicine
	09:55 a.m. Integrated proteogenomic deep sequencing and analytics accurately identify the tumor non-canonical immunopeptidome	Chloe Chong* Ludwig Institute for Cancer Research
	10:15 a.m. Secondary immune resistance mechanisms induced by therapeutic cancer vaccines which prevent tumor regression and foster recurrences	Sjoerd van der Burg Leiden University
	10:40 a.m. Mitochondrial DNA drives absopal responses to radiation that are inhibited by autophagy	Lorenzo Galluzzi Weill Cornell Medical College
Session 8: Vaccination strategies - Session Chairperson: Özlem Türeci		
11:00 a.m. 01:00 p.m.	11:00 a.m. New insights on the mechanisms regulating in situ vaccination by radiotherapy	Sandra Demaria Weill Cornell Medical College
	11:25 a.m. NA cancer vaccines & combination with "standard of care" therapies	Sebastian Kreiter BioNTech AG
	11:50 a.m. <i>Not available at the moment of printing</i>	Özlem Türeci BioNTech AG
	12:15 p.m. Interim results from CLASSICAL-Lung, a phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC patients who progressed on prior anti-PDx therapy	Elizabeth Evans* Vaccinex
	12:30 p.m. Novel epitope derived from PBK (PDZ-binding kinase), a cancer testis antigen, allows CD8+ T cell recognition of pediatric brain tumors	Michelle R. Brault* Fred Hutchinson Cancer Research Center
12:45 p.m. Ribosome profiling predicts novel unannotated open reading frames that contribute peptides to the MHC class I immunopeptidome in healthy and cancer cells and can be a source of neoantigens	Tamara Ouspenskaia* Broad Institute	
01:00 p.m. 03:00 p.m.	Lunch 01:15 p.m. - 02:45 p.m. - "Plenary Lunch Meeting 2" MEET-THE-EDITORS of Cancer Immunology Research, Oncolmmunology, Nature Medicine, Nature Reviews Clinical Oncology & Science - Concomitantly Poster Session B	

Time	Session	Speakers
Session 9: New trends in technology & informatics - Session Chairperson: E. John Wherry		
03:00 p.m. 04:30 p.m.	03:00 p.m. MHC genotype shapes the oncogenic mutational landscape	Hannah Carter University of California San Diego
	03:25 p.m. Mechanisms of T cell exhaustion and role in immunotherapy of cancer	E. John Wherry Institute for immunology, University of Pennsylvania Perelman School of Medicine
	03:50 p.m. Proteogenomics and immunopeptidomics for the development of personalized cancer immunotherapy	Michal Bassani-Sternberg Lausanne University Hospital
	04:15 p.m. Opposing immune and genetic forces shape oncogenic programs in synovial sarcoma	Livnat Jerby* Broad Institute
04:30 p.m. 05:00 p.m.	Coffee Break	
Session 10: TME analysis - Session Chairperson: Miriam Merad		
05:00 p.m. 06:30 p.m.	05:00 p.m. Context dependent impact of B cells on cancer clinical outcome	Wolf Hervé Fridman Centre de Recherche des Cordeliers
	05:25 p.m. Learning the rules of human cancer immunity	Nir Hacohen Massachusetts General Hospital and Broad Institute
	05:50 p.m. Myeloid cell contribution to antitumor immunity	Miriam Merad Icahn School of Medicine at Mount Sinai
	06:15 p.m. Identification of a DC1 immuno-regulatory module that is associated with tumor antigen uptake and partially driven by TAM receptor AXL	Barbara B. Maier* Icahn School of Medicine at Mount Sinai Hospital
06:30 p.m. 08:00 p.m.	Poster Session B continued	
08:00 p.m.	Gala dinner Boarding start: 08:00 p.m. Last Boarding: 09:00 p.m. Expected return to the dock: 11:30 p.m. Be careful, make your arrangements to ensure arriving on-time. Do not forget your wristband. If you do not have it, you will not be able to board. Boats leave at 9:00 p.m. No delay will be accepted.	

*proffered abstract

*proffered abstract

Saturday, September 28, 2019

Time	Session	Speakers
Session 11: IO crosstalk and metabolism - Session Chairperson: Ursula Grohmann		
09:00 a.m. 11:00 a.m.	09:00 a.m. Metabolic interactions between deleterious immune populations and the tumor microenvironment	Greg M. Delgoffe University of Pittsburgh
	09:30 a.m. Immunometabolism modulation by PSGL-1 signaling in tumor-specific T cells	Jennifer L. Hope* Sanford Burnham Prebys Medical Discovery Institute
	09:50 a.m. An Intracellular Spatial Dynamics Dictates the Catalytic Versus Signaling Function of Immunoregulatory IDO1	Ursula Grohmann University of Perugia
	10:20 a.m. Neoantigen-driven remodelling of the T cell landscape in NSCLC	James L. Reading* University College London
	10:40 a.m. Incessant ER stress responses promote dendritic cell dysfunction in ovarian cancer	Chang-Suk Chae* Weill Cornell Medical College
Session 12: Microbiota in oncoimmunology - Session Chairperson: Jennifer A. Wargo		
11:00 a.m. 01:00 p.m.	11:00 a.m. Molecular mimicry between cancer and enterophage antigens: relevance for PD-1 blockade	Laurence Zitvogel Gustave Roussy Cancer Center
	11:30 a.m. Intraepithelial lymphocytes undertake skin immunosurveillance by sensing Skint1	Duncan R. McKenzie* The Francis Crick Institute
	11:45 a.m. Targeting the microbiome in cancer immunotherapy	Giorgio Trinchieri National Cancer Institute
	12:15 p.m. Investigating immune-microbiota interaction in genetically engineered mouse model of lung cancer	Chengcheng Jin* Massachusetts Institute of Technology
	12:30 p.m. The role of the microbiome in response and toxicity to therapy	Jennifer A. Wargo The University of Texas MD Anderson Cancer Center

